Wolfe Research downgrades Scholar Rock Holding to Peer Perform from Outperform

Wolfe Research downgraded Scholar Rock Holding from Outperform to Peer Perform. The change in rating may impact investor sentiment and stock performance.

Original reporting
Published Nov 12, 2026, 3:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 3:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wolfe Research downgrades Scholar Rock Holding to Peer Perform from Outperform — source image
Decision brief

The 30-second read

$SRRKBearishMed
01

Why it matters

A downgrade typically triggers sell‑side pressure, but the effect may be muted if the stock already priced in weak sentiment.

02

Market read

The downgrade provides a fresh, actionable signal for traders holding or considering SRRK.

03

What to watch

Potential pipeline milestones or partnership news not yet disclosed.

Relevance 5/10Novelty 6/10Timing: today

Background

Analyst rating changes are a common catalyst for price movement in micro‑cap stocks.

Company-level read

Ticker impact

$SRRKBearishMedium confidence
Context

Wolfe Research downgraded Scholar Rock Holding to Peer Perform from Outperform.

Expected impact

likely downside pressure as investors price in the lower rating

Evidence & confidence

Analyst downgrades typically prompt short‑term selling, especially for a small‑cap biotech.

Market effects

May weigh on other small‑cap biotech stocks as analysts reassess risk.

Limited to U.S. markets where the stock trades.

Minimal; impact confined to the company's niche sector.

Counterpoint

The downgrade could be premature if upcoming trial data exceed expectations.

Key entities

  • Wolfe Research

    Equity research provider issuing the downgrade.

  • Scholar Rock Holding

    Biotech firm focused on drug development platforms.

Related articles

$SRRKMedAI 8/10

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

$SRRKLow

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.